Integrated global pharmaceutical company Dr Reddy's Laboratories Limited said on Friday it has initiated the process with the Drugs Controller General of India (DCGI) for emergency use authorisation of human adenoviral vector-based platform vaccine candidate Sputnik V.
As part of the review process, Dr Reddy's will present the safety profile of the phase two study and interim data of phase three study which is expected to complete by February 21.
Dr.Reddys C-chairman and Managing Director G V Prasad said in a statement, "The efficacy of Sputnik V was reported to be 91.6 percent by the Lancet, which is an impressive development in the fight against Covid-19. The initiation of the emergency use authorization process will be a critical step forward for us in ensuring speedy access to the Sputnik V vaccine in India."
In September 2020, Dr Reddy's partnered with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V and for its distribution rights in India. Sputnik V has demonstrated an efficacy rate of 91.6 percent in interim analysis of phase three clinical trial which included data on 19,866 volunteers in Russia, who received both the first and second doses of the vaccine.
Sputnik V maintained a consistent efficacy at 91.8 percent even among the group of 2, 144 volunteers over 60 years old. The vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia on August 11 last year and became the world's first registered vaccine against Covid-19 based on the human adenoviral vector platform.
Sputnik V is one of only three vaccines in the world with an efficacy of 91.6 percent and has most authorizations granted with 26 countries globally. The vaccine has already been administered to more than 20 lakh people worldwide.
Russia's Sputnik V vaccine authorised in 26 countries: RDIF
Turkey may launch production of Sputnik V vaccine against corona
Russia's Sputnik V COVID-19 vaccine is approved by Pakistan for emergency use
